On November 12, METIS TECHBIO-P fell 4.31% in Regular Trading, trading at HK$10.64, with turnover of HK$21.61 million.
The latest disclosed item was the company’s October monthly share capital update, which showed no new issuance, repurchase, cancellation, or treasury share changes, while ordinary shares, H shares, and registered capital remained unchanged and public float compliance was maintained.
Recent background catalysts had included inclusion in the Hong Kong exchange’s artificial intelligence index and a strategic collaboration with Eli Lilly on an AI-driven extrahepatic LNP delivery platform. Those developments had previously supported attention on the stock, but the newest disclosure was neutral and did not provide an additional capital-markets catalyst.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments